Crispr Theraptc (NASDAQ:CRSP) Insider Tyler Dylan-Hyde Sells 15,000 Shares

Crispr Theraptc (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.57, for a total transaction of $278,550.00. Following the sale, the insider now directly owns 167,727 shares of the company’s stock, valued at approximately $3,114,690.39. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Crispr Theraptc (CRSP) opened at 18.34 on Friday. The company’s market cap is $744.44 million. Crispr Theraptc has a one year low of $11.63 and a one year high of $25.00. The company has a 50-day moving average of $17.38 and a 200 day moving average of $17.51.

Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company’s quarterly revenue was up 350.0% on a year-over-year basis. Analysts anticipate that Crispr Theraptc will post ($2.43) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Crispr Theraptc (NASDAQ:CRSP) Insider Tyler Dylan-Hyde Sells 15,000 Shares” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/08/19/crispr-theraptc-nasdaqcrsp-insider-tyler-dylan-hyde-sells-15000-shares-updated.html.

A number of hedge funds have recently added to or reduced their stakes in CRSP. IHT Wealth Management LLC purchased a new stake in Crispr Theraptc during the first quarter valued at approximately $110,000. Wells Fargo & Company MN raised its stake in Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new stake in Crispr Theraptc during the second quarter valued at approximately $206,000. Vanguard Group Inc. purchased a new stake in Crispr Theraptc during the second quarter valued at approximately $273,000. Finally, Monashee Investment Management LLC raised its stake in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares in the last quarter. Institutional investors own 24.08% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Cann assumed coverage on shares of Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating for the company. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $21.92.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

What are top analysts saying about Crispr Theraptc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Crispr Theraptc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit